
News|Videos|December 4, 2025
Navigating Adverse Reactions in GLP-1 Treatment
Author(s)Judith Hey-Hadavi, Nicole Snow
Advertisement
Episodes in this series

This episode explores the mechanisms underlying GLP-1 adverse reactions, strategies to minimize GI side effects, and patient-specific factors influencing tolerability. Nicole Snow discusses monitoring and titration approaches tailored to individual patient responses, while Judith Hey-Hadavi emphasizes integrating safety data with clinical decision-making and the importance of managing expectations. Both speakers highlight how dosing, prior exposure, and patient physiology contribute to the overall safety profile of GLP-1 therapies.
Advertisement
Related to this article

Liquid chromatography–tandem mass spectrometry (LC–MS/MS) reveals distinct sphingolipid patterns in anorexia and obesity.

Leon Niezen and Gert Desmet discuss uncertainty-driven LC method development, peak overlap, and moving from in silico to real data.

Leon Niezen and Gert Desmet describe how predictive uncertainty can make automated LC method development more reliable.

Liquid chromatography–mass spectrometry (LC–MS) serum profiling ties lysine compounds to lupus kidney disease.

Liquid chromatography-mass spectrometry (LC–MS) growth lifts Waters Q3; MOBILion ion mobility buy expands proteomics.

Liquid chromatography–tandem mass spectrometry (LC–MS/MS) measures galactose-1-phosphate in dried blood spots to monitor galactosemia.
Advertisement
Advertisement
Trending on LCGC International
1
AI/ML Now: Toxicity Prediction for Unknown LC–HRMS Features Using Machine Learning
2
LCGC Blog: Building a Career Series That Goes Beyond the Surface
3
From 9000 Clues to a Clinical Test: Mass Spectrometry-Driven Lipidomics for Early Cancer Detection
4
Industry Roundup: Waters Posts Strong Third Quarter as LC–MS and Chromatography Consumables Drive Growth, Acquires Ion Mobility Pioneer MOBILion
5








